Kyntra Bio Inc - Company Profile
Powered by 
All the sales intelligence you need on Kyntra Bio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kyntra Bio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kyntra Bio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kyntra Bio Inc (Kyntra) is a biopharmaceutical company focused on developing novel therapies in the fields of cancer biology and anemia. The company's main activities include the research and development of innovative treatments for life-threatening conditions such as metastatic pancreatic cancer, locally advanced pancreatic cancer, and chemotherapy-induced anemia. Major products under development include Pamrevlumab, a human monoclonal antibody, and Roxadustat, an oral small molecule inhibitor. Kyntra collaborates with partners like AstraZeneca and Astellas Pharma Inc. for the commercialisation of its products in various regions. The company's products are primarily targeted at healthcare providers and patients dealing with cancer and anemia-related conditions. Kyntra operates in multiple geographic locations, with a focus on markets in China, Europe, Japan, and other countries. Kyntra is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
350 Bay Street, Suite 100 #6009, San Francisco, California, 94133
Website
www.kyntrabio.com
Telephone
1 415 9781200
No of Employees
34
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KYNB (NASD)
Revenue (2024)
$6.4M
-78.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
485.6%
(2024 vs 2023)
Market Cap*
$30.6M
Net Profit Margin (2024)
XYZ
1,873.4%
(2024 vs 2023)
* As of and is in US$
Kyntra Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Roxadustat |
| Pamrevlumab |
| FG-3246: Metastatic Castration-Resistant Prostate Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In September, the company sold its subsidiary, FibroGen China, to AstraZeneca for US$220 million. |
| 2025 | Regulatory Approval | In August, the company received approval from the China State Administration for Market Regulation to sell FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Ltd. |
| 2025 | Plans/Strategy | In February, the company announced plans to sell its China subsidiary, FibroGen China to AstraZeneca for US$160 million. |
Competitor Comparison
| Key Parameters | Kyntra Bio Inc | Amgen Inc | Boehringer Ingelheim International GmbH | Kyowa Kirin Co Ltd | 3SBio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | Japan | China |
| City | San Francisco | Thousand Oaks | Ingelheim am Rhein | Chiyoda-Ku | Shenyang |
| State/Province | California | California | Rheinland-Pfalz | Tokyo | Liaoning |
| No. of Employees | 34 | 31,500 | 54,300 | 5,161 | 6,268 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James A. Schoeneck | Chairman | Executive Board | 2020 | 68 |
| Thane Wettig | Chief Executive Officer; Director | Executive Board | 2023 | 61 |
| David DeLucia | Chief Financial Officer; Senior Vice President | Senior Management | 2024 | 37 |
| Mairead Carney | Executive Director -Clinical Operations and Strategic Outsourcing | Senior Management | - | - |
| Christine L. Chung | Senior Vice President - China Operations | Senior Management | 2007 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer